BCAX Strangle Strategy
BCAX (Bicara Therapeutics Inc. Common Stock), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.
BCAX (Bicara Therapeutics Inc. Common Stock) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $1.15B, a beta of -0.56 versus the broader market, a 52-week range of 7.8-24.25, average daily share volume of 578K, a public-listing history dating back to 2024, approximately 55 full-time employees. These structural characteristics shape how BCAX stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of -0.56 indicates BCAX has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a strangle on BCAX?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current BCAX snapshot
As of May 15, 2026, spot at $20.13, ATM IV 66.10%, IV rank 11.16%, expected move 18.95%. The strangle on BCAX below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on BCAX specifically: BCAX IV at 66.10% is on the cheap side of its 1-year range, which favors premium-buying structures like a BCAX strangle, with a market-implied 1-standard-deviation move of approximately 18.95% (roughly $3.81 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated BCAX expiries trade a higher absolute premium for lower per-day decay. Position sizing on BCAX should anchor to the underlying notional of $20.13 per share and to the trader's directional view on BCAX stock.
BCAX strangle setup
The BCAX strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With BCAX near $20.13, the first option leg uses a $21.14 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed BCAX chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 BCAX shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $21.14 | N/A |
| Buy 1 | Put | $19.12 | N/A |
BCAX strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
BCAX strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on BCAX. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on BCAX
Strangles on BCAX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the BCAX chain.
BCAX thesis for this strangle
The market-implied 1-standard-deviation range for BCAX extends from approximately $16.32 on the downside to $23.94 on the upside. A BCAX long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current BCAX IV rank near 11.16% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on BCAX at 66.10%. As a Healthcare name, BCAX options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to BCAX-specific events.
BCAX strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. BCAX positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move BCAX alongside the broader basket even when BCAX-specific fundamentals are unchanged. Always rebuild the position from current BCAX chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on BCAX?
- A strangle on BCAX is the strangle strategy applied to BCAX (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With BCAX stock trading near $20.13, the strikes shown on this page are snapped to the nearest listed BCAX chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are BCAX strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the BCAX strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 66.10%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a BCAX strangle?
- The breakeven for the BCAX strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current BCAX market-implied 1-standard-deviation expected move is approximately 18.95%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on BCAX?
- Strangles on BCAX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the BCAX chain.
- How does current BCAX implied volatility affect this strangle?
- BCAX ATM IV is at 66.10% with IV rank near 11.16%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.